Capnocytophaga keratitis

George Alexandrakis, Luigi A. Palma, Darlene Miller, Eduardo C Alfonso

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose: To review the clinical course, treatment, and visual outcomes of keratitis caused by the gram negative rod Capnocytophaga. Design: Retrospective, noncomparative case series. Participants: Ten patients with culture-proven unilateral Capnocytophaga keratitis examined at the Bascom Palmer Eye Institute between January 1, 1989, and December 31, 1998. Intervention: All patients underwent standard diagnostic microbiologic evaluation, and topical antimicrobial therapy was instituted. A penetrating keratoplasty or enucleation was performed in some patients. Main Outcome Measures: The changes in visual acuity and clinical response to antimicrobial therapy. Results: Predisposing factors were present in all patients. Cultures identified Capnocytophaga species at a mean of 7.5 days. Initial topical treatment consisted of an aminoglycoside and vancomycin in four patients, a quinolone or aminoglycoside alone in two patients each, and ofloxacin with vancomycin or tobramycin with ceftazidime in one patient each. After the microbiologic identification of Capnocytophaga, treatment in four patients was changed to intensive, topical clindamycin. Five of the 10 eyes were medically cured (3 of these eyes underwent penetrating keratoplasty for corneal scarring), and 5 eyes required enucleation. The indications for enucleation included persistent infection with development of endophthalmitis or blind, painful eye. Five of the 10 eyes achieved 20/80 or better final visual acuity. Four of these five eyes were treated with topical clindamycin. Conclusions: Important factors in achieving a good visual outcome in Capnocytophaga keratitis include early microbiologic identification and intensive therapy with topical clindamycin. Capnocytophaga should be included in the differential diagnosis of bacterial keratitis in patients with suggestive predisposing factors or with protracted keratitis unresponsive to treatment. (C) 2000 by the American Academy of Ophthalmology.

Original languageEnglish
Pages (from-to)1503-1506
Number of pages4
JournalOphthalmology
Volume107
Issue number8
DOIs
StatePublished - Nov 20 2000

Fingerprint

Capnocytophaga
Keratitis
Clindamycin
Penetrating Keratoplasty
Aminoglycosides
Vancomycin
Causality
Visual Acuity
Therapeutics
Eye Enucleation
Tobramycin
Ofloxacin
Endophthalmitis
Ceftazidime
Quinolones
Cicatrix
Differential Diagnosis
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Capnocytophaga keratitis. / Alexandrakis, George; Palma, Luigi A.; Miller, Darlene; Alfonso, Eduardo C.

In: Ophthalmology, Vol. 107, No. 8, 20.11.2000, p. 1503-1506.

Research output: Contribution to journalArticle

Alexandrakis, George ; Palma, Luigi A. ; Miller, Darlene ; Alfonso, Eduardo C. / Capnocytophaga keratitis. In: Ophthalmology. 2000 ; Vol. 107, No. 8. pp. 1503-1506.
@article{6e497e6d4fcc418989db3b7063048490,
title = "Capnocytophaga keratitis",
abstract = "Purpose: To review the clinical course, treatment, and visual outcomes of keratitis caused by the gram negative rod Capnocytophaga. Design: Retrospective, noncomparative case series. Participants: Ten patients with culture-proven unilateral Capnocytophaga keratitis examined at the Bascom Palmer Eye Institute between January 1, 1989, and December 31, 1998. Intervention: All patients underwent standard diagnostic microbiologic evaluation, and topical antimicrobial therapy was instituted. A penetrating keratoplasty or enucleation was performed in some patients. Main Outcome Measures: The changes in visual acuity and clinical response to antimicrobial therapy. Results: Predisposing factors were present in all patients. Cultures identified Capnocytophaga species at a mean of 7.5 days. Initial topical treatment consisted of an aminoglycoside and vancomycin in four patients, a quinolone or aminoglycoside alone in two patients each, and ofloxacin with vancomycin or tobramycin with ceftazidime in one patient each. After the microbiologic identification of Capnocytophaga, treatment in four patients was changed to intensive, topical clindamycin. Five of the 10 eyes were medically cured (3 of these eyes underwent penetrating keratoplasty for corneal scarring), and 5 eyes required enucleation. The indications for enucleation included persistent infection with development of endophthalmitis or blind, painful eye. Five of the 10 eyes achieved 20/80 or better final visual acuity. Four of these five eyes were treated with topical clindamycin. Conclusions: Important factors in achieving a good visual outcome in Capnocytophaga keratitis include early microbiologic identification and intensive therapy with topical clindamycin. Capnocytophaga should be included in the differential diagnosis of bacterial keratitis in patients with suggestive predisposing factors or with protracted keratitis unresponsive to treatment. (C) 2000 by the American Academy of Ophthalmology.",
author = "George Alexandrakis and Palma, {Luigi A.} and Darlene Miller and Alfonso, {Eduardo C}",
year = "2000",
month = "11",
day = "20",
doi = "10.1016/S0161-6420(00)00227-X",
language = "English",
volume = "107",
pages = "1503--1506",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Capnocytophaga keratitis

AU - Alexandrakis, George

AU - Palma, Luigi A.

AU - Miller, Darlene

AU - Alfonso, Eduardo C

PY - 2000/11/20

Y1 - 2000/11/20

N2 - Purpose: To review the clinical course, treatment, and visual outcomes of keratitis caused by the gram negative rod Capnocytophaga. Design: Retrospective, noncomparative case series. Participants: Ten patients with culture-proven unilateral Capnocytophaga keratitis examined at the Bascom Palmer Eye Institute between January 1, 1989, and December 31, 1998. Intervention: All patients underwent standard diagnostic microbiologic evaluation, and topical antimicrobial therapy was instituted. A penetrating keratoplasty or enucleation was performed in some patients. Main Outcome Measures: The changes in visual acuity and clinical response to antimicrobial therapy. Results: Predisposing factors were present in all patients. Cultures identified Capnocytophaga species at a mean of 7.5 days. Initial topical treatment consisted of an aminoglycoside and vancomycin in four patients, a quinolone or aminoglycoside alone in two patients each, and ofloxacin with vancomycin or tobramycin with ceftazidime in one patient each. After the microbiologic identification of Capnocytophaga, treatment in four patients was changed to intensive, topical clindamycin. Five of the 10 eyes were medically cured (3 of these eyes underwent penetrating keratoplasty for corneal scarring), and 5 eyes required enucleation. The indications for enucleation included persistent infection with development of endophthalmitis or blind, painful eye. Five of the 10 eyes achieved 20/80 or better final visual acuity. Four of these five eyes were treated with topical clindamycin. Conclusions: Important factors in achieving a good visual outcome in Capnocytophaga keratitis include early microbiologic identification and intensive therapy with topical clindamycin. Capnocytophaga should be included in the differential diagnosis of bacterial keratitis in patients with suggestive predisposing factors or with protracted keratitis unresponsive to treatment. (C) 2000 by the American Academy of Ophthalmology.

AB - Purpose: To review the clinical course, treatment, and visual outcomes of keratitis caused by the gram negative rod Capnocytophaga. Design: Retrospective, noncomparative case series. Participants: Ten patients with culture-proven unilateral Capnocytophaga keratitis examined at the Bascom Palmer Eye Institute between January 1, 1989, and December 31, 1998. Intervention: All patients underwent standard diagnostic microbiologic evaluation, and topical antimicrobial therapy was instituted. A penetrating keratoplasty or enucleation was performed in some patients. Main Outcome Measures: The changes in visual acuity and clinical response to antimicrobial therapy. Results: Predisposing factors were present in all patients. Cultures identified Capnocytophaga species at a mean of 7.5 days. Initial topical treatment consisted of an aminoglycoside and vancomycin in four patients, a quinolone or aminoglycoside alone in two patients each, and ofloxacin with vancomycin or tobramycin with ceftazidime in one patient each. After the microbiologic identification of Capnocytophaga, treatment in four patients was changed to intensive, topical clindamycin. Five of the 10 eyes were medically cured (3 of these eyes underwent penetrating keratoplasty for corneal scarring), and 5 eyes required enucleation. The indications for enucleation included persistent infection with development of endophthalmitis or blind, painful eye. Five of the 10 eyes achieved 20/80 or better final visual acuity. Four of these five eyes were treated with topical clindamycin. Conclusions: Important factors in achieving a good visual outcome in Capnocytophaga keratitis include early microbiologic identification and intensive therapy with topical clindamycin. Capnocytophaga should be included in the differential diagnosis of bacterial keratitis in patients with suggestive predisposing factors or with protracted keratitis unresponsive to treatment. (C) 2000 by the American Academy of Ophthalmology.

UR - http://www.scopus.com/inward/record.url?scp=0033777975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033777975&partnerID=8YFLogxK

U2 - 10.1016/S0161-6420(00)00227-X

DO - 10.1016/S0161-6420(00)00227-X

M3 - Article

C2 - 10919898

AN - SCOPUS:0033777975

VL - 107

SP - 1503

EP - 1506

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 8

ER -